Home > Journals > Minerva Cardioangiologica > Past Issues > Minerva Cardioangiologica 2013 June;61(3) > Minerva Cardioangiologica 2013 June;61(3):255-62

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA CARDIOANGIOLOGICA

A Journal on Heart and Vascular Diseases


Official Journal of the Italian Society of Angiology and Vascular Pathology
Indexed/Abstracted in: EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,695


eTOC

 

  INTERVENTIONAL INNOVATIONS: NOVEL THERAPIES AND THE BEST NEW DEVICE CONCEPTS FOR 2013


Minerva Cardioangiologica 2013 June;61(3):255-62

Copyright © 2013 EDIZIONI MINERVA MEDICA

language: English

Which patients could benefit the most from bioresorbable vascular scaffold implant: from clinical trials to clinical practice

Latib A. 1, Costopoulos C. 1, Naganuma T. 2, Colombo A. 2

1 Interventional Cardiology Unit, San Raffaele Scientific Institute, Milan, Italy; 2 Interventional Cardiology Unit, EMO-GVM Centro Cuore Columbus, Milan, Italy


PDF  


Bioresorbable scaffold technology has evol-ved over the last few years with a number of devices either available or under clinical and preclinical investigation. The absence of a permanent metallic segment in the treated vessel wall has the potential of addressing some of the issues still encountered with metallic drug-eluting stents (DES) despite improvements in stent platform, polymer and drug elution. To date however, the use of bioresorbable vascular scaffolds (BVS) has largely been restricted to patients recruited into clinical trials with a relatively small number of “real-world” patients treated with these devices. Here we explore the issue of BVS use in “real-world” patients and try to identify, on the basis of our experience, the subset of patients that could benefit the most.

top of page

Publication History

Cite this article as

Corresponding author e-mail

info@emocolumbus.it